Drugs / CBG002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06705725 | Dec 2024 → Oct 2027 expected | plasma cell myeloma | Carbiogene Therapeutics Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04706936 | Apr 2021 → Oct 2023 | refractory plasma cell neoplasm | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBG-002 | “This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM).” NCT04706936 ↗ |
| Modality | Cell therapy | “Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.” NCT04706936 ↗ |
| Route | Intravenous | “All subjects were intravenous administrated with CBG-002.” NCT04706936 ↗ |